Added to YB: 2024-01-08
Pitch date: 2024-01-08
VAXX [bearish]
Vaxxinity, Inc.
+99.96%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.
Market Cap
$25.3K
Pitch Price
$0.81
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.28
P/E
-0.00
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
Show full summary:
[SHORT] Vaxxinity (VAXX) - When Your Biggest Corporate Asset is a Private Plane
VAXX: Biotech developing vaccines for chronic diseases raises red flags. Mgmt lacks notable scientific achievements, co-founders from investment/law. No CFO, but spent 2/3 of assets on private plane amid $50M/yr cash burn, $43M cash, going concern risk. Suggests unsustainable lifestyle funding via share dilution.
Read full article (2 min)